Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2021-03-12 M&A Activity
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
425 Filing
M&A Activity Classification · 95% confidence The document is a communication filed pursuant to Rule 425 under the Securities Act of 1933, related to the proposed acquisition of Alexion Pharmaceuticals by AstraZeneca. It includes a workplace post update about the acquisition, information about the filing of a registration statement on Form F-4, and details about the forthcoming proxy statement/prospectus. The document does not contain actual financial statements or detailed financial analysis but rather provides an update on the merger process and references filings to be made. It is a communication related to merger activity but is not itself a merger filing like a definitive proxy or tender offer document. Given the nature of the document as a Rule 425 communication (a type of merger-related communication), the appropriate classification is M&A Activity (TAR). The document length (7140 characters) and content confirm it is not a brief announcement or a report publication announcement, but a substantive merger communication.
2021-03-12 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, submitted to the SEC as a report of a foreign issuer. It details share awards granted to Persons Discharging Managerial Responsibilities (PDMRs) under the AstraZeneca Deferred Bonus Plan and Performance Share Plan. The document includes specific transaction details such as the number of shares granted, prices, dates, and the nature of the transactions. It is not an annual or quarterly report, nor an earnings release or management discussion. It specifically reports insider share transactions related to directors and senior management. Therefore, it fits the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is over 7,000 characters, indicating it is a full report rather than a brief announcement. Hence, the classification is DIRS with high confidence.
2021-03-09 English
Director/PDMR Shareholding
Remuneration Information Classification · 99% confidence The document is identified by the RNS Number (6809R) and the header 'Transactions by Persons Discharging Managerial Responsibilities'. It details the granting of share awards (stock options/grants) to senior executives (Pascal Soriot, CEO, and Marc Dunoyer, CFO) under specific company plans (AZDBP and AZPSP). This type of mandatory disclosure regarding insider transactions by management falls directly under the definition of Director's Dealing (DIRS). Although it references the Annual Report for performance details, the core content is the transaction notification itself.
2021-03-09 English
DESIGNATION OF EU HOME MEMBER STATE FOR EU SECURITIES REGULATION PURPOSES
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content focuses on the designation of the EU home member state for securities regulation purposes following Brexit, specifically selecting Sweden as the home member state. It includes regulatory compliance information and notification obligations under Swedish law. The document is relatively short (4280 characters) and serves as a regulatory announcement rather than a full financial report or detailed filing. It does not contain financial statements, earnings data, or detailed management discussion. It is primarily a regulatory filing informing about compliance and jurisdictional designation. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-03-04 English
Designation of EU home member state
Regulatory Filings Classification · 98% confidence The document is very short (3774 characters) and begins with an 'RNS Number' and a date/time stamp, indicating it is a regulatory news service announcement. The text explicitly states that AstraZeneca is announcing a change regarding its 'Designation of EU home member state for EU securities regulation purposes' and concludes with the statement: 'This information is information that AstraZeneca PLC is obliged to make public pursuant to the Swedish Securities Market Act. The information was submitted for publication...'. This structure—a brief announcement of a regulatory event, published via RNS, and stating an obligation to make information public—fits the definition of a general regulatory filing that doesn't fit a more specific category like ER, 10-K, or DIV. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-03-04 English
US COURT DECISION FAVOURS SYMBICORT PATENTS
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains a legal update about a US court decision favoring AstraZeneca's patents related to Symbicort. The content is primarily a regulatory announcement about litigation outcomes and intellectual property rights, not a financial report or detailed management discussion. The document is about 5783 characters, which is relatively short and focused on a specific event rather than comprehensive financial data or management commentary. It does not contain financial statements or detailed analysis typical of annual or interim reports, nor is it a transcript, capital update, or governance change. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-03-03 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.